HUE036408T2 - A leukotrién-termelés benzodioxán inhibitorai - Google Patents

A leukotrién-termelés benzodioxán inhibitorai

Info

Publication number
HUE036408T2
HUE036408T2 HUE12711504A HUE12711504A HUE036408T2 HU E036408 T2 HUE036408 T2 HU E036408T2 HU E12711504 A HUE12711504 A HU E12711504A HU E12711504 A HUE12711504 A HU E12711504A HU E036408 T2 HUE036408 T2 HU E036408T2
Authority
HU
Hungary
Prior art keywords
leukotriene production
benzodioxane
inhibitors
benzodioxane inhibitors
leukotriene
Prior art date
Application number
HUE12711504A
Other languages
English (en)
Inventor
Asitha Abeywardane
Michael J Burke
Thomas Martin Kirrane
Matthew Russell Netherton
Anil Kumar Padyana
Keenan Lana Louise Smith
Hidenori Takahashi
Michael Robert Turner
Qiang Zhang
Qing Zhang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45922814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE036408(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HUE036408T2 publication Critical patent/HUE036408T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HUE12711504A 2011-03-14 2012-03-13 A leukotrién-termelés benzodioxán inhibitorai HUE036408T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161452329P 2011-03-14 2011-03-14

Publications (1)

Publication Number Publication Date
HUE036408T2 true HUE036408T2 (hu) 2018-07-30

Family

ID=45922814

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12711504A HUE036408T2 (hu) 2011-03-14 2012-03-13 A leukotrién-termelés benzodioxán inhibitorai

Country Status (28)

Country Link
US (2) US8551982B2 (hu)
EP (1) EP2686310B1 (hu)
JP (1) JP5640162B2 (hu)
KR (1) KR101893756B1 (hu)
CN (1) CN103415513B (hu)
AP (1) AP3339A (hu)
AU (1) AU2012229172B2 (hu)
BR (1) BR112013023517B1 (hu)
CA (1) CA2835617C (hu)
CL (1) CL2013002546A1 (hu)
CO (1) CO6771439A2 (hu)
DK (1) DK2686310T5 (hu)
EA (1) EA023876B1 (hu)
EC (1) ECSP13012958A (hu)
ES (1) ES2660493T3 (hu)
GE (1) GEP20156347B (hu)
HU (1) HUE036408T2 (hu)
IL (1) IL227805A (hu)
MA (1) MA35089B1 (hu)
MX (1) MX355309B (hu)
PE (1) PE20140976A1 (hu)
PL (1) PL2686310T3 (hu)
SG (1) SG193454A1 (hu)
TN (1) TN2013000362A1 (hu)
TR (1) TR201802550T4 (hu)
TW (1) TWI551593B (hu)
UY (1) UY33950A (hu)
WO (1) WO2012125598A1 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125598A1 (en) 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
US9139567B2 (en) 2011-07-19 2015-09-22 Boehringer Ingelheim International Gmbh Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase
AR091315A1 (es) * 2012-03-06 2015-01-28 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno
US9662339B2 (en) * 2012-03-06 2017-05-30 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production for combination therapy
EP2827849A4 (en) 2012-03-23 2015-11-18 Univ Leland Stanford Junior TREATMENT OF PULMONARY HYPERTONIA WITH LEUKOTRIENHEMMERN
TW201416354A (zh) 2012-07-17 2014-05-01 Boehringer Ingelheim Int 白三烯生成抑制劑
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
BR112015022227A2 (pt) * 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
WO2014151761A1 (en) * 2013-03-15 2014-09-25 Ariad Pharmaceuticals, Inc. Novel choline kinase inhibitors
WO2015009611A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
WO2015009609A1 (en) * 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
JP6749002B2 (ja) 2014-10-08 2020-09-02 国立研究開発法人理化学研究所 植物成長促進剤及び植物成長促進方法
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190500A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y uso de los mismos
CN106866692A (zh) * 2017-03-30 2017-06-20 毛阿龙 具有苯并1,4‑二氧杂环己二烯酮结构的fshr拮抗剂的制备方法
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP3801559A4 (en) 2018-05-31 2022-03-02 Celltaxis, LLC METHOD FOR REDUCING LUNG EXACERBATIONS IN PATIENTS SUFFERING FROM RESPIRATORY DISEASE
AU2021325431B2 (en) 2020-08-14 2024-01-18 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918092A (en) * 1983-12-21 1990-04-17 Merck Frosst Canada, Inc. Leukotriene antagonists
US5120758A (en) 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US5585492A (en) 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
DE19821003A1 (de) 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1332136A2 (en) 2000-10-26 2003-08-06 Pfizer Products Inc. Pyrimidine-2,4,6-trione metalloproteinase inhibitors
US20060019269A1 (en) 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
RU2423353C1 (ru) 2002-12-20 2011-07-10 Глэксо Груп Лимитед Новые производные бензазепина
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
ATE472543T1 (de) 2005-01-07 2010-07-15 Pfizer Prod Inc Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren
CN101189012A (zh) 2005-03-31 2008-05-28 詹森药业有限公司 苯基和吡啶基lta4h调节剂
NZ566788A (en) 2005-09-21 2012-10-26 Decode Genetics Ehf Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
EP1968961A2 (en) 2005-12-21 2008-09-17 Decode Genetics EHF Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
AU2006327243A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation
CN102946877B (zh) 2010-03-18 2019-07-05 香港科技大学 乳突果及其分离的化合物在制备用于治疗神经疾病的药物中的用途
WO2012125598A1 (en) 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
US9139567B2 (en) 2011-07-19 2015-09-22 Boehringer Ingelheim International Gmbh Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase
US9662339B2 (en) 2012-03-06 2017-05-30 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production for combination therapy
AR091315A1 (es) 2012-03-06 2015-01-28 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno
TW201416354A (zh) 2012-07-17 2014-05-01 Boehringer Ingelheim Int 白三烯生成抑制劑

Also Published As

Publication number Publication date
MA35089B1 (fr) 2014-05-02
EP2686310A1 (en) 2014-01-22
NZ614109A (en) 2015-01-30
CO6771439A2 (es) 2013-10-15
IL227805A (en) 2017-06-29
EA201301019A1 (ru) 2014-03-31
KR101893756B1 (ko) 2018-09-03
DK2686310T3 (en) 2018-02-26
US9133146B2 (en) 2015-09-15
TN2013000362A1 (en) 2015-01-20
JP2014511826A (ja) 2014-05-19
AP3339A (en) 2015-07-31
US20130196973A1 (en) 2013-08-01
AU2012229172A1 (en) 2013-08-29
US20130345195A1 (en) 2013-12-26
ECSP13012958A (es) 2013-11-29
GEP20156347B (en) 2015-08-10
WO2012125598A1 (en) 2012-09-20
TWI551593B (zh) 2016-10-01
TW201302723A (zh) 2013-01-16
ES2660493T3 (es) 2018-03-22
JP5640162B2 (ja) 2014-12-10
BR112013023517A2 (pt) 2016-12-06
MX2013010457A (es) 2013-10-28
CA2835617C (en) 2020-07-21
CN103415513A (zh) 2013-11-27
SG193454A1 (en) 2013-10-30
UY33950A (es) 2012-09-28
CN103415513B (zh) 2016-01-20
TR201802550T4 (tr) 2018-03-21
MX355309B (es) 2018-04-16
US8551982B2 (en) 2013-10-08
EP2686310B1 (en) 2017-12-13
CA2835617A1 (en) 2012-09-20
DK2686310T5 (en) 2018-07-09
PL2686310T3 (pl) 2018-06-29
PE20140976A1 (es) 2014-08-28
BR112013023517B1 (pt) 2021-08-31
AP2013007044A0 (en) 2013-08-31
CL2013002546A1 (es) 2014-04-04
IL227805A0 (en) 2013-09-30
EA023876B1 (ru) 2016-07-29
AU2012229172B2 (en) 2017-02-09
KR20140021600A (ko) 2014-02-20

Similar Documents

Publication Publication Date Title
AP3339A (en) Benzodioxane inhibitors of leukotriene production
HK1245110B (zh) 異喹啉酮的固體形式
ZA201309561B (en) Novel inhibitor compounds of phosphodiestarase type 10a
HK1204604A1 (en) Stereoselective total synthesis of noribogaine
GB201104096D0 (en) Production of graphene
ZA201300238B (en) Oxadiazole inhibitors of leukotriene production
IL230976A (en) Crystalline forms of Czebitaxel
GB2504804B (en) Method of making super-hard constructions
EP2793780A4 (en) METHOD FOR PRODUCING A TAMPON
HK1199252A1 (en) Inhibitors of nedd8-activating enzyme nedd8-
ZA201308852B (en) Process of making beta-hydroxyamino compounds
GB201120696D0 (en) Production of mono-cystalline silicon
EP2801073A4 (en) METHOD FOR CHARACTERIZING CRATED MATERIALS
PT2751081T (pt) Forma polimórfica de pitavastatina cálcica
EP2623580A4 (en) PROCESS FOR PRODUCING BETA-SIALON
ZA201301747B (en) Oxadiazole inhibitors of leukotriene production
GB201004096D0 (en) Production of polyhydroalkanoates
EP2694705A4 (en) MICROFABRICATION OF TUNNELS
EP2697334A4 (en) PROCESS FOR THE PRODUCTION OF RETAINING AGENTS
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
EP2766862A4 (en) METHOD FOR MANAGING PRODUCTS
ZA201402773B (en) Use of phenylpyrazolin-3-carboxylates for improving plant yield
IL230977A (en) A crystalline form of relapaldib
GB201114798D0 (en) Method of modifying surfaces
ZA201401439B (en) Use of 5-phenyl-or 5-benzyl-2isoxazoline-3carboxylates for improving plant yield